Date:5/8/2009

est and other income 95 918 Net loss $(9,292) $(13,098) Basic and diluted net loss per common share $(0.24) $(0.34) Weighted average shares outstanding 38,204 38,059 Balance Sheet Data (in thousands) March 31, 2009 December 31, 2008 (Unaudited) (Note 1) Cash, cash equivalents and securities $54,214 $63,314 Receivables from collaborations 9,847 11,982 Total assets 72,602 84,692 Accumulated deficit (258,560) (249,268) Stockholders' equity 38,517 46,426 Note 1: Derived from audited financial statements.

'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
2. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
3. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
4. BioCryst Updates Peramivir Clinical Development Plan
5. BioCryst Provides Forodesine HCl Update
6. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
7. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
8. USAID Provides $5M in Emergency Support as Swine Flu Spreads
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
10. Strativa Pharmaceuticals Provides Product Pipeline Update
11. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update